Skip to content

Clinical trials

Phase 2 Neuromyelitis Optica trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neuromyelitis Optica Phase: Phase 2 Clear all

19 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20091
20132
20141
20151
20191
20212
20222
20232
20241
20253
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed8
Recruiting3
Active, not recruiting2
Unknown status2
Withdrawn2
Not yet recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Tianjin Medical University General Hospital5
Amgen1
Anastasia Vishnevetsky, MD, MPH1
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1
Fred Hutchinson Cancer Center1
Guangzhou JOYO Pharma Co., Ltd1
Johns Hopkins University1
Massachusetts General Hospital1
Michael, Levy M.D.,Ph.D.1
Nihon Pharmaceutical Co., Ltd1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neuromyelitis Optica19
Multiple Sclerosis2
Autoimmune Diseases1
Autoimmune Diseases of the Nervous System1
Demyelinating Diseases1
Diffuse Cerebral Sclerosis of Schilder1
Lambert-Eaton Myasthenic Syndrome1
Marijuana Abuse1
Multiple Sclerosis, Relapsing-Remitting1
Muscle Spasticity1

Trials

Showing 76 to 19 of 19. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.